A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-Cell or B-Cell Precursor Acute Lymphoblastic Leukaemia or T-Cell Non-Hodgkin's Lymphoma.

Trial Profile

A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-Cell or B-Cell Precursor Acute Lymphoblastic Leukaemia or T-Cell Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Forodesine (Primary) ; Forodesine (Primary)
  • Indications Acute lymphoblastic leukaemia; T cell lymphoma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Mundipharma International
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in France.
    • 17 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Planned end date changed from 1 May 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top